Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?

被引:104
|
作者
Kessler, TM [1 ]
Danuser, H [1 ]
Schumacher, M [1 ]
Studer, UE [1 ]
Burkhard, FC [1 ]
机构
[1] Univ Bern, Dept Urol, CH-3010 Bern, Switzerland
关键词
botulinum A toxin; idiopathic detrusor overactivity; injections into the detrusor; neurogenic detrusor overactivity;
D O I
10.1002/nau.20105
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
=Aims: To assess and compare the effect of botulinum A toxin (BTX-A) injections into the detrusor in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment. Patients and Methods: in a prospective study, 11 patients with idiopathic and 11 with neurogenic detrusor overactivity resistant to anticholinergic treatment were injected with 300 U of BTX-A (Botox (R)) into the detrusor. Clinical and urodynamic parameters were assessed before and after BTX-A injections. Results: In idiopathic as well as in neurogenic cletrusor overactivity, median daytime frequency decreased significantly from 11 to 4 (P = 0.004) and 12 to 5 (P = 0.001), median nocturia from 3 to 1 (P = 0.004) and 3 to 1 (P = 0.001), and median number of used pads from 5 to 0 (P = 0.001) and 5 to 0 (P = 0.002), respectively. There was a significant increase in median maximum cystometric capacity from 220 to 340 nil (11 = 0.001) and 190 to 410 ml (to instead of) (P = 0.001), median bladder compliance from 20 to 55 ml/cmH(2)O (11 0.001) and 23 to 60 ml/cmH(2)O (P = 0.004) and median post void residual from 10 to 140 nil (P = 0.002) and 30 to 240 ml (P = 0.002), respectively. Median maximum cletrusor pressure decreased significantly from 45 to 29 cmH(2)O (P = 0.002) and 40 to 24 cmH(2)O (P = 0.002), and median detrusor pressure at maximum flow rate from 30 to 14 ml/sec (P = 0.001) and 38 to 21 ml/sec (P = 0.016), respectively. Due to post void residuals > 150 ml following BTX-A injections, de novo clean intermittent self-catheterization was necessary in nine patients (four with idiopathic and five with neurogenic cletrusor overactivity) and in one patient (with idiopathic detrusor overactivity) a suprapubic catheter was placed. The effect of BTX-A injections lasted for a median time of 5 months in both idiopathic and neurogenic detrusor overactivity. There was no significant difference in idiopathic compared to neurogenic detrusor overactivity in regard to clinical and urodynamic parameters assessed before and after BTX-A injections. Conclusions: BTX-A injections into the cletrusor have a significant and comparable but temporally limited effect in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment. Neurourol. Urodynam. 24:231-236,2005. 0 2005 Wiley-Liss, Inc.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [41] Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity
    Christopher Dowson
    Mohammad Shamim Khan
    Prokar Dasgupta
    Arun Sahai
    Nature Reviews Urology, 2010, 7 : 661 - 667
  • [42] Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
    Averbeck, Marcio Augusto
    INTERNATIONAL BRAZ J UROL, 2022, 48 (06): : 988 - 989
  • [43] Results of botulinum toxin: A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity
    Game, X.
    Roumiguie, M.
    Guillotreau, J.
    Doumerc, N.
    Bordier, B.
    Sallusto, F.
    Malavaud, B.
    Rischmann, P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E466 - U18
  • [45] Botulinum toxin for detrusor overactivity
    Dmochowski, R.
    TOXICON, 2013, 68 : 71 - 71
  • [46] Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections
    Game, Xavier
    Castel-Lacanal, Euelyne
    Bentaleb, Youssef
    Thiry-Escudie, Isabelle
    De Boissezon, Xavier
    Malavaud, Bernard
    Marque, Philippe
    Rischmann, Pascal
    EUROPEAN UROLOGY, 2008, 53 (03) : 613 - 619
  • [47] Botulinum toxin: A potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity
    Casanova, N.
    McGuire, E.
    Fenner, D. E.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 (03) : 305 - 311
  • [48] Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity
    Conte, A.
    Giannantoni, A.
    Proietti, S.
    Giovannozzi, S.
    Fabbrini, G.
    Rossi, A.
    Porena, M.
    Berardelli, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (05) : 725 - 732
  • [49] Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice
    Knuepfer, Stephanie
    Juenemann, Klaus-Peter
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (01) : 34 - 42
  • [50] Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections
    Karsenty, G.
    Corcos, J.
    Schurch, B.
    Ruffion, A.
    Chartier-Kastler, E.
    PROGRES EN UROLOGIE, 2007, 17 (03): : 568 - 575